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Protocol for understanding acute
sarcopenia: a cohort study to characterise
changes in muscle quantity and physical
function in older adults following
hospitalisation
Carly Welch1,2,3,4* , Carolyn A. Greig1,5,6,7, Tahir Masud1,8,9,10, Thomas Pinkney3,11 and Thomas A. Jackson1,2,3,12
Abstract
Background: Older adults are vulnerable to the effects of acute sarcopenia (acute muscle insufficiency) following
hospitalisation. However, this condition remains poorly characterised to date. It is hypothesised that acute
sarcopenia arises due to a combination of bed rest and inflammatory surge. This study aims to characterise
changes in muscle quantity and function, determining which factors (clinical and biological) are most predictive,
and how these relate to change in physical function at 13 weeks.
Methods: This study will include three groups of patients aged 70 years and older; patients undergoing elective
colorectal surgery, patients admitted for emergency abdominal surgery, and patients admitted under general
medicine with acute bacterial infections. Changes in muscle quantity (Bilateral Anterior Thigh Thickness with
ultrasound and bioelectrical impedance analysis) and muscle function (muscle strength, physical performance)
within 1 week of hospitalisation or surgery will be characterised, with follow-up of patients at 13 weeks. Physical
function will be measured using the Patient Reported Outcome Measures Information System, and the Short
Physical Performance Battery (or gait speed alone within 1 week of surgery).
Discussion: This study will fully characterise changes in muscle quantity and function in hospitalised older adults
and enable risk stratification towards targeted interventions in clinical practice. The results of this study will inform
further research involving interventions to ameliorate changes.
Trial registration: ClinicalTrials.gov Identifier: NCT03858192; Prospectively registered 28th February 2019.
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Background
Acute sarcopenia is an emerging condition of acute
muscle insufficiency; older adults are considered particu-
larly vulnerable to its effects following hospitalisation
[1]. The European Working Group on Sarcopenia in
Older People 2 (EWGSOP2) defines sarcopenia as re-
duced muscle strength with reduced muscle quantity or
quality; cut-off values to meet criteria are usually set
2.0–2.5 standard deviations below the mean of a young
adult healthy reference population. Additional demon-
stration of low physical performance is defined as severe
sarcopenia. The revised definition (EWGSOP2) includes
a distinction between acute and chronic sarcopenia;
acute sarcopenia is defined as incident sarcopenia within
6 months, normally following a stressor event [2]. How-
ever, acute sarcopenia has been poorly characterised to
date [1].
The biological mechanisms, clinical risk factors, longer
term outcomes, and most effective management strat-
egies of acute sarcopenia are currently unknown. Acute
sarcopenia is considered to be caused by a combination
of heightened inflammation and muscle disuse during
bedrest. Studies involving healthy volunteers have dem-
onstrated that bedrest is associated with declines in
muscle quantity, strength, and aerobic performance, and
that this effect is exacerbated by age [3, 4]. Acute illness
(e.g. acute bacterial infection) and major surgery are as-
sociated with systemic inflammatory response [5] and
endocrinological stress response (e.g. increased cortisol,
decreased dehydroepiandrosterone sulfate (DHEA-s))
[6]. Pro-inflammatory cytokines activate pathways lead-
ing to increased muscle protein degradation [7] and
hypercortisolaemia has been shown to exacerbate loss of
muscle quantity during bedrest [8]. It has been postu-
lated that acute sarcopenia may be partially recoverable,
but may increase the risk of chronic sarcopenia over
time [1]. It is proposed to be related to a combination of
acute inflammatory surge and bedrest during hospitalisa-
tion [1]. Characterising acute sarcopenia will enable
greater understanding of the significance of changes in
clinical practice, and allow risk stratification towards tar-
geted interventions.
EWGSOP traditionally recommended Computed
Tomography (CT), Magnetic Resonance Imaging, or
Dual-Energy X-Ray Absorptiometry to measure muscle
quantity [9]. However, these tests cannot be used at the
bedside and have limitations when used serially [10].
Ultrasound measurement of Bilateral Anterior Thigh
Thickness (BATT) has excellent inter-rater and intra-
rater variability [11]. EWGSOP2 supports use of ultra-
sound for clinical assessment of sarcopenia [2] and a
consensus protocol has been proposed [12]. Bioelectrical
Impedance Analysis (BIA) is an alternative non-invasive
tool that provides estimates of lean mass. Muscle
quantity measured by BIA has been shown to correlate
with BATT [13], however, BIA is more greatly affected
by fluid balance [14, 15]. BIA is also not currently rec-
ommended for use on people with implantable cardiac
devices, although research suggests this is likely to be
safe [16].
Colorectal surgery is commonly performed on older
adults [17]. It is not typically associated with cachexia,
when performed for localised colorectal cancer [18];
metastatic cancer is known to be associated with in-
creased risk of cachexia compared to localised cancer
[19]. Colorectal surgery patients do not typically present
with disease-associated pre-operative functional decline
associated [20], as compared to orthopaedic or vascular
surgery, where impairments in function are presenting
symptoms of the illnesses themselves [21, 22]. This of-
fers the opportunity for pre-insult measurements to be
taken prior to hospitalisation. Previous studies have
demonstrated acute declines in handgrip strength and
muscle quantity using BIA in older adults admitted elec-
tively for colorectal surgery [23]. Acute reductions in
BATT and usual gait speed were also demonstrated in
our pilot study, which was used to refine this protocol
[24]. Interestingly, an apparent increase in BATT was
demonstrated immediately postoperatively [24]; this may
be related to fluid balance but warrants further investi-
gation [25]. However, emergency admitted patients may
be at the greatest risk of declines in muscle quantity and
function due to increased inflammation. Within the UK,
hospitalised older adults are most commonly admitted
to general medicine wards [26]. Studies involving med-
ical and orthopaedic patients have shown variable
changes in muscle quantity and function in hospitalised
older adults [23, 27, 28], and changes have not been




To clinically and biologically characterise acute sarcope-
nia in older hospital populations, assessing for within
group differences in elective colorectal surgery, emer-
gency surgery, and general medicine patients. This will
enable determination of mechanisms and identification
of potential intervention strategies.
Design and setting
This is a single site cohort study at the Queen Elizabeth
Hospital Birmingham (QEHB), involving 56 elective
colorectal, 56 emergency abdominal surgery, and 56
medical patients. QEHB is a large tertiary hospital, with
a firmly embedded research infrastructure. In the elect-
ive cohort, measurements will be performed in preopera-
tive assessment clinic, within 48 h of surgery, at 7 days
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postoperatively (+/− 2 days), and at 13 weeks postopera-
tively (+/− 1 week). In the emergency surgery cohort, we
aim to recruit participants preoperatively where possible.
Where this is not possible, we will recruit participants
within 48 h of emergency surgery; further assessments
will be performed at 7 days postoperatively (+/− 2 days),
and at 13 weeks postoperatively (+/− 1 week). Medical
patients will be recruited within 48 h of admission with
further assessment at 7 days post-admission (+/− 2 days),
and at 13 weeks post-admission (+/− 1 week). The time-
frame of 13 weeks has been chosen pragmatically as a
timeframe that was considered important to our patient
and public involvement panel that could be feasibly con-
ducted without high drop-out rates. The full study
schema is shown in Fig. 1.
Characteristics of participants
The elective cohort will include patients expected to
undergo major colorectal surgery, the emergency surgery
cohort will include emergency admitted patients who
have undergone or are planned to undergo emergency
abdominal surgery, and the medical cohort will include
emergency admitted patients with (or suspected) acute
bacterial infections. Participants aged 70 years or older at
time of recruitment will be included in all cohorts. Par-
ticipants who are unable to provide written informed
consent at time of recruitment will not be included in
the elective cohort, although specific consent will be ob-
tained for participants to remain in the study if they lose
capacity, including details of any named consultee. In
the emergency surgery and medical cohorts, personal or
professional consultee declaration will be obtained if the
participant is unable to provide written informed con-
sent. Participants who are unable to understand verbal
English, who were unable to mobilise prior to admission
to hospital, or who have a life expectancy of less than
30 days will be excluded from all cohorts.
Processes and interventions
Table 1 shows the complete schedule of assessments
that will be performed during this study. We describe




Rectus Femoris (RF) and Vastus Intermedius (VI) mus-
cles in both legs will be assessed using two-dimensional
Fig. 1 Study schema for recruitment and follow-up of each included cohort
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B-mode ultrasonography with a linear probe, as previ-
ously described [11]. This will be performed at first visit,
immediately postoperatively (where applicable), at 7 day
follow-up, and at 13 week follow-up. Participants will be
positioned semi-upright with knees resting at 10–20°
and advised to relax their muscles. The distance from
greater trochanter to knee lateral joint line will be re-
corded and a mark placed on the skin mid-way between
the two points. Measurements will be taken in line hori-
zontally with these marks. Contact gel will be applied.
Muscle thickness will be measured with the probe in
transverse position. Depth will be adjusted until the
femur and overlying structures are visible. The probe
will be positioned such that the widest area of the RF ap-
pears over the midpoint of the femur. Frozen images at
this location will be taken with the probe held in max-
imal relaxation.
Thickness measurements of subcutaneous tissues (SC),
RF, and VI in a vertical line will be recorded, not includ-
ing the fascia. Three frozen images will be used for all
patients; a further image will be taken if there is greater
than 10% variability between measurements. The mean
of each reading will be used for analysis. BATT will be
calculated as total thickness of right VI + right RF + left
VI + left RF. BATT: SC ratio (BATT-SCR) will be
calculated as BATT divided by total thickness of right
SC + left SC [24]. Where possible, cross-sectional area of
the right and left RF will be measured. All measurements
will be performed by an investigator with training in tak-
ing these measurements. The reliability of BATT has
been shown to be excellent when using the same proto-
col and same machine (intraclass coefficients > 0.9 for
both intra-rater and inter-rater variability) [11].
A further image will be taken in the longitudinal pos-
ition at each visit. Images will be saved and downloaded
for assessment. RF and SC echogenicity will be deter-
mined using grey-scale analysis on Image J software.
Pennation angle will be measured by the angle of inser-
tion of the fascicles within the VI to the deep aponeur-
osis. The mean measure from up to three fascicles
measured on each image will be used for analysis [29].
Bioelectrical impedance analysis (BIA)
BIA measurements will be taken at the first visit, imme-
diately postoperatively (where applicable), at 7 day
follow-up, and at 13 week follow-up using a multi-
frequency analyser; Bodystat Quadscan 4000. This will
not be performed if the participant has an implanted
permanent pacemaker or defibrillator. The participant
will be positioned lying semi-upright with knees resting
Table 1 Schedule of study procedures. This chart shows all possible visits for each cohort and assessments that would be expected
to take place for each participant in each cohort. Visits marked with * may not take place for all participants
Visit Elective cohort Emergency cohort Medical cohort
A B C D A* B C D B C D
Demographics, observations, medications, medical history, blood tests as
part of routine care
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Review of CT scans performed as part of routine clinical care (if available) ✓ ✓
BATT using ultrasound ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
BIA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Handgrip strength ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Short Physical Performance Battery ✓ ✓ ✓ ✓ ✓ ✓
Gait speed alone ✓ ✓
Physical function by PROMIS ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Katz ADLs and Lawton IADLs ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Mini Nutritional Assessment (Full) ✓ ✓ ✓ ✓ ✓ ✓
Extra frailty assessments ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Venepuncture (optional) ✓ ✓ ✓ ✓ ✓
Application of physical activity recorder (optional) ✓ ✓ ✓
Delirium assessment ✓ ✓ ✓ ✓ ✓ ✓ ✓
Fluid balance assessment ✓ ✓ ✓ ✓ ✓ ✓ ✓
Participant feedback ✓ ✓ ✓
PROMIS Patient Reported Outcome Measures Information System, ADLs Activities of Daily Living.
Visit A: Preoperative assessment; in preoperative assessment clinic for elective cohort, on ward prior to surgery for emergency surgery cohort (where possible) –
not applicable to medical cohort.
Visit B: Immediate; Within 48 h of surgery for surgical cohorts, within 48 h of admission for medical cohort.
Visit C: One week; 7 (+/− 2) days after surgery (surgical cohorts) or after admission (medical cohort).
Visit D: Three months; 13 (+/− 1) week after surgery (surgical cohorts) or admission (medical cohort).
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in extension on the examination couch, hospital bed or
equivalent. The assessor will ensure that limbs are not
touching. Two electrodes will be placed on the right
foot; one below the base of the toes and the other on the
ankle between the medial and lateral malleoli. The red
alligator clip will be attached to the electrode nearest the
toes and the black to the one at the ankle. A further two
electrodes will be placed on the right hand; one behind
the knuckles and the other on the wrist next to the ulnar
head. The red alligator clip will be attached to the elec-
trode nearest the fingers and the black to the one at the
wrist. Electrodes will be placed transversely so that the
non-stick electrode connector is facing the researcher.
The Bodystat Quadscan 4000 includes a quality control
feature; an impedance graph is displayed prior to results
being displayed. If the graph shows a smooth curve, the
investigator will proceed to record results. If there are
any bumps in the graph, the investigator will recheck
lead and limb position prior to repeating the analysis.
Single measurements will be recorded at each visit.
All returned measures including prediction marker,
impedance, resistance, reactance, phase angle, fat weight,
lean weight, dry lean weight, Fat Free Mass Index
(FFMI), Body Fat Mass Index (BFMI), total body water,
extracellular water, and intracellular water will be re-
corded. Skeletal muscle mass (SMM) will be additionally
estimated using three previously validated equations: 1)
SMM= 0.566 x Fat Free Mass (lean mass) [30]; 2)
SMM= [((height2/ resistance) × 0.401) + (sex ×
3.825) + (age x − 0.071)] + 5.102. In the second equation,
height is in cm, for sex male = 1, female = 0, and age is
in years [31]. 3) SMM= − 3.964 + (0.227 x (height2/ re-
sistance)) + (0.095 x weight) + (1.384 x sex) + (0.064 x
reactance) [32]. For all equations, the skeletal muscle
index (SMI) will be calculated through the formula
SMI = SMM/ height2, where height is in m, for compari-
son with normative populations [33]. Height and weight
are recorded for all patients at the site of this study as
part of routine clinical care. For the elective cohort,
height will be measured in preoperative assessment
clinic using a stadiometer. For the emergency surgery
and medical cohorts, height will be recorded using a sta-
diometer where possible. Where this is not possible,
height will be taken from previous clinical records if
these are available, or from patient report. If none of
these methods are possible, then height may be esti-
mated by measuring ulna length and conversion as per
British Association of Parenteral and Enteral Nutrition
guidelines [34]. If an estimate has been used, this will be
recorded. The same height will be used for all visits.
L3-CT using imaging performed during routine medical care
CT scans will be reviewed if these have been performed
as part of routine care and are available. Skeletal muscle
index will be calculated at the level of the third lumbar ver-
tebra (L3) on the first image with both vertebral spines vis-
ible using local hospital site Picture Archiving and
Communication Software. This will be calculated by manu-
ally identifying skeletal muscles and automatic calculation
of cross-sectional area; this value will be corrected for
height2 [35]. Total psoas area (TPA) will also be calculated
on the same slice. The right and left psoas muscle borders
will be manually outlined and TPA will be calculated within
the selected area. This measurement will be corrected for
height2 [36]. This will be performed by the investigating
geriatrician who is trained in use of the software.
Muscle function assessment
Muscle strength
Handgrip strength will be measured at first visit, imme-
diately postoperatively (where applicable), at 7 day
follow-up, and at 13 week follow-up using a Jamar hand-
held dynamometer. Where the participant can sit in a
chair, handgrip strength will be measured with the elbow
flexed at 90O and the forearm supinated. If measure-
ments are taken in the bed this will be recorded; mea-
surements will instead be performed in the most feasible
upright position. Participants will be asked to “squeeze
as hard as [they] can”. Handgrip strength will be mea-
sured twice on each side and the highest recording of
the four measurements will be used for analysis [37].
Physical performance
The Short Physical Performance Battery (SPPB) is a stan-
dardised measure of physical performance that has been
shown to be sensitive to change and provides an objective
measure of physical function [38]. SPPB consists of usual
gait speed, side-by-side stand, semi-tandem stand, tandem
stand, and five chair stands (as quickly as they can). A
total score of 12 is derived, with a lower score represent-
ing reduced physical performance. The SPPB will be mea-
sured at baseline and 3 month follow-up for the elective
cohort, at 3 month follow-up for the emergency surgery
cohort, and at all visits for the medical cohort. Gait speed
alone will be measured at 7 day follow-up for both surgical
cohorts. Gait speed will be measured by asking the partici-
pants to walk a four metre course at their “usual pace”.
Gait speed will not be performed at recruitment in the
emergency surgery cohort as this is considered unfeasible
due to pain and immediate operative recovery. Measuring
chair stands at 1 week post-operatively would cause in-
creased abdominal strain, therefore, gait speed alone will
be measured at this timepoint.
Physical function – patient reported outcome measures
information system (PROMIS®)
PROMIS physical function is a validated measure of
physical function [39, 40]. PROMIS is an initiative that
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compares participant responses to a reference popula-
tion and derives a T-score, where 50 is the mean, and 10
is the standard deviation. PROMIS will be measured at
baseline and 3 month follow-up for all groups. The raw
scores will be entered into the HealthMeasures scoring




Participant demographics, observations, medications,
medical history, smoking and alcohol history, and blood
test results performed as part of routine care will be col-
lected. Medical comorbidities will be used to derive the
Geriatric Index of Comorbidity [41]. Number of admis-
sions and falls over the previous year will be recorded.
Falls will be recorded from participant report. Any new
information including changes in weight, observations,
medications, or blood tests will be recorded at each visit,
dependent on when these are recorded as part of usual
clinical care.
Nutritional assessment
The Mini-Nutritional Assessment (MNA®) is a validated
assessment tool for nutritional status [42]. Much of the
information required will be collected elsewhere. Add-
itional information that will be collected will include
food intake, specifically protein and fruit or vegetable in-
take, and fluid intake from participant report. Mid-arm
circumference will be measured at the mid-point be-
tween the olecranon and acromium. Calf circumference
will be measured as the widest part of calf. These mea-
surements will be taken for the dominant limb. The
MNA (full form) will be assessed at baseline visits and
13 week follow-up visits for each group.
Frailty assessment
Frailty will be assessed at first visit, 7 day follow-up, and
13 week follow-up using the Frailty Index (FI) [43], 9-
point Clinical Frailty Scale (CFS) [44], and phenotype
definition [45]. Activities of Daily Living (ADLs) will be
assessed using Katz (basic ADLs) [46] and Lawton (in-
strumental ADLs) [47] tools. The phenotypic diagnosis
of frailty will be made if the participant meets three out
of five criteria: low gait speed, low handgrip strength,
weight loss, self-reported exhaustion or low physical ac-
tivity. Cut-offs used in the original phenotype diagnosis
will be used for gait speed, handgrip strength, and
weight loss. Self-reported exhaustion will be defined if
the participant answers “most of the time” or “all of the
time” to how often over the last week they had felt that
either “everything [they] did was an effort” or they
“could not get going” [45]. Physical activity will be de-
fined through self-report by asking the participant if over
the last 3 months they have performed no weight-
bearing physical activity, been for a short walk once/
month or less, or spent more than 4 hours/ day sitting
[48]. The FI will be calculated by counting the total
number of deficits present out of 36 defined criteria, and
dividing by 36. These criteria have been adapted for sec-
ondary care use from those previously validated in a UK
community setting to form the electronic frailty index
(Supplementary File 1) [49]. The CFS will be determined
by the investigating geriatrician after clinical review and
after all other information has been collected. The inves-
tigating geriatrician will determine this immediately after
reviewing the participant by considering ADLs, physical
function, self-reported exhaustion, and symptomatic
burden reported by the participant.
Delirium screening and assessment
Delirium will be diagnosed by the investigating geriatri-
cian as per the Diagnostic and Statistical Manual of
Mental Disorders 5 [50]. Participants will first be
screened for evidence of delirium at each visit using the
Single Question in Delirium “Do you think this patient
has been more confused lately?” [51]. The investigating
geriatrician will review notes and ask staff caring for the
participant, family members, and the participant them-
selves. The participant themselves will be specifically
asked “Has anything strange been happening?”, such as
experiencing hallucinations. Where possibility of delir-
ium is raised upon screening or during other assess-
ments, the investigating geriatrician will perform further
assessments to formally diagnose delirium by testing at-
tention by months of the year backwards [52], con-
sciousness by the Modified Richmond Agitation and
Sedation Scale [53], and cognition by the Abbreviated
Mental Test Score (Supplementary File 2).
Fluid balance assessment
Fluid balance will be assessed and recorded during all
visits during hospitalisation. Fluid balance will be
assessed by clinical assessment, review of input/ out-
put charts, and BIA measurements. Clinical assess-
ment by the investigating geriatrician will include
review of skin turgor, mucus membranes, oedema,
Jugular Venous Pressure level, trends in observations
e.g. blood pressure, and patient presentation. The
overall fluid status will be recorded as hypovolaemic,
euvolaemic, or hypervolaemic for the participant over-
all. However, if unilateral oedema is present in a sin-
gle limb this will be recorded. BIA measurements of
TBW, ECW, ICW, and third space water will be re-
corded separately and assessed against all other avail-
able information of fluid balance.
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Other outcome data
Further routinely collected data that will be recorded
will include (as applicable) the operation performed,
peri-operative blood loss, type of post-operative anal-
gesia (patient-controlled analgesia or epidural), postop-
erative complications, length of stay, discharge
destination, other hospital admissions within the 3 month
follow-up period, histological diagnosis (cancer vs. not),
and 1 year mortality.
Participant feedback
There is no standardised assessment tool for measuring
test acceptability. However, a multi-faceted construct of
acceptability has been proposed, which reflects the ex-
tent to which people receiving a healthcare investigation
or intervention consider it to be appropriate. This con-
struct consists of the affective attitude of the individual,
procedure burden, individual ethicality (individual value
system), intervention coherence (participant understand-
ing), opportunity costs, perceived effectiveness, and self-
efficacy (confidence that they can perform the necessary
behaviour) [54]. Considering this construct, we have de-
vised a questionnaire that assesses each of these aspects
separately for muscle quantity (for both ultrasound and
BIA), handgrip strength, and gait speed testing (Supple-
mentary file 2). These four aspects have been chosen as
these will be measured most frequently for all partici-
pants in this study and have potential for direct transla-
tion into clinical practice. This will be administered to
all participants at their final visit.
Venepuncture (optional)
Blood samples will be taken using the BD vacutainer
Safety-Lok™ system in sterile vacutainers without addi-
tives (BD biosciences). Samples will normally be taken
peripherally but may be taken centrally or via arterial
lines if these are in place as part of routine clinical care.
Samples will be taken at first visit, and where possible,
within 48 h of surgery in the surgical cohorts. Blood
samples will be centrifuged within 30 min to 1 hour of
collection, within the University of Birmingham Re-
search Laboratories, within QEHB. Serum and plasma
samples will be removed using calibrated pipettes and
stored at -80 °C prior to further analysis. Serum and/or
plasma concentration levels of high sensitivity C-
Reactive Protein (hsCRP), Dehydroepiandrosterone sul-
fate (DHEA-s), cortisol, 25-OH vitamin D, Interleukin 6
(IL-6), Tumour Necrosis Factor Alpha (TNF-α), and
Insulin-like Growth Factor (IGF-1) will be measured
using Enzyme-Linked Immunosorbent Assays or other
appropriate tests. Further additional biomarkers may be
tested as appropriate. Remaining serum and/or plasma
samples will be stored for use in future ethically
approved research within the University of Birmingham
Research Laboratories.
Fitbit inspire physical activity quantification (optional)
The Fitbit Inspire will be applied to the non-dominant
wrist during hospitalisation where this is agreed by the
participant or consultee. This will record activity statis-
tics during hospitalisation including number of steps
taken, distance travelled, and sedentary time. Summary
statistics will be recorded for up until 30 days after hos-
pitalisation. Participants will be advised to wear the
monitor all the time. They will be supplied with a char-
ger and advised to charge the device every 5 days when
at rest, such as at night time. Position changes (e.g. sit to
stand) will not be specifically recorded with this device.
Statistical analysis
Power calculation
The sample size for this study has been calculated by
considering estimates of the precision of outcomes; 80%
power and 5% significance level have been used in calcu-
lating this sample size. Allowing for 25% loss to follow-
up from a sample size of 56, based on a paired t-test, the
following clinically important changes may be detected
with a sample size of 45 in each group (all changes are
powered to be bidirectional and may be identified at
multiple timeframes):
 Change of 6 for t-score derived from physical
function measured by PROMIS (Mean 50, SD = 10)
– from baseline to 1 week and/or from baseline to
13 weeks. This is validated from previous studies
[39].
 Change of 0.66 cm in BATT (Mean 3.6 cm, SD = 1.1
cm) – from baseline to 1 week and/or from baseline
to 13 weeks. This is consistent with clinical change
detected in our pilot study (mean loss of 0.76 cm)
[24].
 Change of 0.6 in skeletal muscle mass index
measured using BIA (Mean 8.5, SD = 1) – from
baseline to 1 week and/or from baseline to 13 weeks.
This is consistent with change detected in previous
studies, consistent with acute sarcopenia [28].
 Change of 6 kg in handgrip strength (Mean 23,
SD = 10) – from baseline to 1 week and/or from
baseline to 13 weeks. This is validated from previous
studies [37].
Data analysis
Data analysis will be conducted using IBM SPSS® Ver-
sion 22. Results for each cohort will be analysed separ-
ately, although secondary data analysis will be conducted
on all groups together. Interim analysis is planned with
involvement from a patient and public involvement
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panel. Outcomes will be summarised at baseline, 7 days
postoperatively, and 13 weeks postoperatively. The data
analysis of the primary research question will include
the following models:
 Unadjusted model with PROMIS at 13 weeks as the
outcome of interest, and the secondary outcome as
the covariate of interest (i.e. change in BATT,
handgrip strength and/or gait speed from baseline to
7 days).
 Adjusted model with PROMIS at 13 weeks as the
outcome of interest, and the secondary outcome as
the covariate of interest (i.e. change in BATT,
handgrip strength and/or gait speed from baseline to
7 days), with adjustment for the baseline PROMIS
score, and patient demographics (e.g. age, gender).
 Model with PROMIS at 13 weeks as the outcome of
interest, with adjustment for baseline PROMIS, and
all secondary outcomes as covariates to establish the
strength of association between those secondary
outcomes and the primary outcome. This model will
be used to establish which of the secondary
outcomes (i.e. change in BATT, handgrip strength
and/or gait speed from baseline to 7 days) is most
strongly associated with change in PROMIS at 13
weeks.
Change in PROMIS rather than change in SPPB,
which can be considered an objective measure of phys-
ical function, has been selected as our primary outcome
for two reasons. Firstly, our patient and public involve-
ment panel considered their own perception of their
physical function to be most important. Although per-
ception of function may differ from objective function,
how function is perceived for them as individuals was
considered more important. Secondly, it will only be
possible to obtain true pre-hospitalisation measures of
SPPB for the elective cohort. PROMIS provides a
method of evaluating physical function prior to admis-
sion in the emergency cohorts. Change in SPPB will be
evaluated as a secondary outcome in the elective cohort.
Acute sarcopenia
Sarcopenia will be defined as per EWGSOP2 as handgrip
strength below 16 kg in women or below 27 kg in men
[2, 55], in combination with low muscle quantity or
quality. Cut-offs for low muscle quantity and quality will
be evaluated comparing the cohort against reference
data in healthy young adults; cut-offs for BATT of 3.85
cm in women and 5.44 cm in men have been proposed
[11]. Severe sarcopenia will be defined as additional
presence of low physical performance; gait speed 0.8 m/s
or less [56] or SPPB of 8 or less [57]. Acute sarcopenia
will be defined as incident sarcopenia compared to
baseline measurements at recruitment. The prevalence
of sarcopenia will be calculated at each visit.
Patient and public involvement
Older adults have been involved in the design and devel-
opment of this research. We will host further discussion
groups when analysing the results (interim and final).
This will be particularly valuable when determining the
significance of unexpected results. The interim meeting
will be of potential value in assessing if any protocol
amendments are necessary. The third discussion group
will also be used to co-produce the study report. The
findings of this research will be disseminated to all par-
ticipants and their advocates through a written sum-
mary. The participants who are enrolled in this study
itself will be the best placed to assess and comment on
the acceptability of the procedures used during this
study. Within the study design itself, we have devised a
questionnaire to derive a multi-faceted acceptability
score for assessment of muscle quantity using ultra-
sound, handgrip strength, and walking speed. We con-
sider that formally interviewing participants could lead
to unnecessary burden, given the time they will have
already dedicated to the study itself. However, any infor-
mal feedback given will be recorded to guide further re-
search and healthcare policy. The final formal meeting
that is planned with our discussion group will encom-
pass a full evaluation of the importance of the results of
this study and will be used to co-produce any protocols
for future research, as well as recommendations for
healthcare policy.
Trial registration
This study was registered on ClinicalTrials.gov (identi-
fier: NCT03858192) on 28th February 2019.
Discussion
This study will fully characterise changes in muscle
quantity and function in a clinical setting and will pro-
vide invaluable information to researchers, clinicians,
and patients. The results of this study have potential to
lead on directly to further interventional studies to
counteract these changes, with particular focus on iden-
tified mechanistic associations and clinical factors to
guide risk stratification. The results may also lead to dir-
ect changes in clinical practice, including the embedding
of our research tools into clinical practice, and changes
in policy, such as promoting early mobilisation. Provid-
ing patients and members of the public with increased
knowledge on their risk of declines in muscle quantity
and function, and what this is likely to mean for them,
can help to empower them in their own decision making
and engagement with treatment and therapy.
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We recognise that there are a number of limitations of
our study. Firstly, this is a single site study, and there-
fore, the results may not be generalisable to the wider
population. Secondly, the cohorts we have included are
disease-specific. However, we consider that our results
will provide proof of concept, which can be used to
guide further research to increase understanding in
other disease populations. As described, our study has
been powered to detect within group differences in the
minimally clinical important differences as derived from
other studies. However, this has not been powered sep-
arately for gender and other covariates (e.g. cancer vs.
not), which may affect measurements. Interim analysis
has been planned and our patient and public involve-
ment panel will be involved in the interpretation of these
results. At this stage, we will review the overall progress
of the study and consider if protocol amendments may
be necessary.
There is some evidence that position can affect measure-
ment of muscle quantity by ultrasound and BIA [58, 59].
However, the results will be compared to a reference group
of young healthy individuals taken in the same position as
we have described, using the same technique [11]. The pos-
ition described is one that we can consider to be feasible
for measurements in a variety of different clinical environ-
ments, whilst ensuring the quadriceps are relaxed. Particu-
lar care will be taken to standardise the position of each
measure for each participant across separate visits. Never-
theless, we acknowledge that due to measurements being
taken in different clinical environment, there may be small
uncontrollable differences in position across visits.
Venepuncture and physical activity recording have
both been included as optional aspects of the study, and
it is not known what percentage of participants will
agree to these. However, venepuncture was previously
included as an optional aspect within our pilot study
and all participants were in agreement with this [24].
We recognise that there will be limitations of physical
activity measurements recorded through the Fitbit In-
spire. These devices will be unable to specifically
measure change in position (e.g. sit to stand). Previ-
ous studies using raw accelerometer data have shown
a floor effect when measuring physical activity in frail,
sedentary older adults [60]. However, physical activity
measures using Fitbits have also shown to correlate
well with raw accelerometer data in studies involving
older adults [61]. The Fitbit Inspire is considered to
be an acceptable device for older adults due to its
simple wristwatch-like design, and their low cost
means that they are potentially utilisable in clinical
practice. Within our study, we will assess the feasibil-
ity of using these devices and assess the validity of
data recorded as covariates and predictors of change
in muscle parameters and physical function.
Despite these limitations, we consider the recruitment
of a complex heterogeneous population to be a strength
of this study. Frail older adults are frequently under-
represented in research studies. It is not possible to be
certain that changes seen in young healthy adults are
concordant with changes in older adults. Determining
the mechanisms involved in the development of acute
sarcopenia will enable risk stratification, and targeted in-
terventions to prevent or even reverse the effects.
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